Edition:
United Kingdom

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

70.14USD
6:44pm GMT
Change (% chg)

$0.13 (+0.19%)
Prev Close
$70.01
Open
$69.90
Day's High
$70.25
Day's Low
$69.80
Volume
386,701
Avg. Vol
709,823
52-wk High
$70.25
52-wk Low
$45.48

Select another date:

BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin

* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN

BRIEF-Baxter International-‍​On Jan 1,Administrative Committee Of Compensation Committee Of Board Approved Amendment To Reorganize Co's, Units Pension Plan

* BAXTER INTERNATIONAL-‍​ON JAN 1,ADMINISTRATIVE COMMITTEE OF COMPENSATION COMMITTEE OF BOARD APPROVED AMENDMENT TO REORGANIZE CO'S,UNITS PENSION PLAN

BRIEF-Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln

* BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS

Baxter expects $70 million hit to fourth-quarter sales from Hurricane Maria

U.S. hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue, due to manufacturing disruptions arising from Hurricane Maria.

UPDATE 2-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria

* Shares slightly lower (Adds share price, CEO comments from analyst call)

Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria

Oct 25 Hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue due to manufacturing disruptions arising from Hurricane Maria.

BRIEF-Baxter provides update on Puerto Rico recovery status post Hurricane Maria

* Baxter provides update on Puerto Rico recovery status post Hurricane Maria

BRIEF-Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​

* Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Baxter International ‍announces commercial launch of new indication for oXiris set​

* Baxter launches first 3-in-1 set for use in continuous renal replacement therapy and sepsis management protocols

BRIEF-Baxter and MATTER Healthcare on patient-driven innovation

* Baxter and MATTER Healthcare Incubator Partner on patient-driven innovation

Select another date: